Invest in an AI-driven platform biotech discovering patented therapeutics and bioactive innovations from natural biodiversity

Alphanosos is a French AI-driven platform biotech transforming the way therapeutic and bioactive innovations are discovered. By combining proprietary artificial intelligence with experimental biology, we identify patentable bioactive compositions from natural biodiversity capable of addressing complex health challenges that conventional approaches struggle to solve.

Over the past decade, the platform has generated multiple patented assets with preclinical and clinical validation, commercialized products, industrial partnerships, and programs spanning infectious diseases, dermatology, oncology, neurological disorders, metabolic diseases, and rare genetic conditions.

We are seeking strategic and financial investors interested in supporting the scale-up of a differentiated discovery platform with multiple paths to value creation. Our business model combines licensing agreements, co-development partnerships, royalties, product commercialization, and long-term therapeutic development, providing both near-term revenue opportunities and significant pharmaceutical upside.

Investment will accelerate business development, clinical validation, platform expansion, manufacturing capabilities, and the advancement of high-potential therapeutic programs. We welcome discussions with venture capital funds, family offices, corporate venture groups, strategic investors, and impact-focused investors seeking exposure to the future of AI-enabled healthcare innovation.